Therefore, MYCN-MV detection in bone marrow plasma has a potential implication as the adjunct diagnosis of MYCN-amplified neuroblastoma, providing an objective clue to support clinical decision of early treatment initiation while awaiting the official pathological report (which usually take a few day). This evidence concerns the gene MYCN and neuroblastoma.